Europe Dengue Vaccines Market

Europe Dengue Vaccines Market Size (2022 To 2027)

The size of the dengue vaccines market in Europe is expected to grow to USD 390 million by 2027 from USD 230 million in 2022, growing at a CAGR of 11.38% from 2022 to 2027.

The growing incidence of dengue and the increasing number of R&D activities propel the European dengue vaccine market growth. In December 2022, France reported 65 local dengue cases. Dengue virus can occur in any age group of people. Dengue comes from the bite of mosquitoes during the rainy season relating to climate change. The patient affected by the dengue virus has symptoms such as sickness, vomiting, and decreased red blood cells, which may even lead to death in severe conditions. Due to rising awareness regarding the seriousness of the problem, the population is showing interest in taking dengue vaccination at the European Vaccination Centre, which is anticipated to promote regional market growth. In addition, the availability of safe and cost-effective dengue vaccination in the European region also supports market growth.

In addition, the growing research centers to develop various types of dengue vaccines is another major factor fuelling the market’s growth rate. Furthermore, owing to the growing complications in patients of the dengue virus, researchers are focusing on developing different types of vaccination based on the data gathered by the healthcare provider and the survey on the people who have previously administered the dengue vaccine and faced side effects.

However, the lack of funding by the European governments for dengue vaccination in some parts of Europe is anticipated to hamper the regional market growth. Furthermore, the lack of awareness regarding the dengue vaccine among people in Europe's underdeveloped and developing countries is another notable factor inhibiting the market’s growth rate. Additionally, the lack of awareness regarding the dengue virus antibodies among many skilled professionals and researchers is hindering the Europe dengue vaccines market.

This research report on the Europe dengue vaccines market has been segmented and sub-segmented into the following categories.

By Category:

• Live Attenuated Vaccines
• Chimeric Live Attenuated Vaccines

By Product:

• CTD-TDV (Dengvaxia)
• Others

By Route of Administration:

• Subcutaneous
• Others

By Application:

• Hospitals and clinic
• Government Institutes
• Specialty Clinics
• Others

By End User:

• Healthcare
• Others

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region held a considerable share of the global market in 2021 and is anticipated to showcase a healthy CAGR during the forecast period owing to the increasing invention of new drugs and approval of novel drugs. In 2022, the European Commission approved a dengue vaccine in two doses for the age group 4 years and above. European health regulators are responsible for the decisions initiated to reduce the mosquito-borne dengue virus for European people. The European government has conducted several awareness programs about the dengue vaccine throughout the region to reduce the death rate caused by the virus. Dengue is caused due to a mosquito which is primarily seen in slum areas and unclean places. Therefore, the leading organization and the government focus on conducting these programs mainly in rural areas with no proper drainage or garbage facilities. They also explain the importance of taking the dengue vaccine in adults and children, which demands market growth in this region.

The UK held a substantial share of the European market in 2021 and is expected to hold good occupancy during the forecast period. Due to the less availability of the dengue vaccine in the United Kingdom, the government has started investing in developing the dengue vaccine in the UK. Research centers are being established to conduct multiple clinical trials for developing dengue vaccines for all age groups.

Germany is one of the promising regional markets in Europe and is anticipated to showcase a healthy CAGR in the coming years. In recent years, a dengue vaccine manufacturing plant has been established in Germany, which helps to supply dengue vaccines throughout the European region. Many key players have invested in the plant, which supports market growth in this region. These plants are well equipped with advanced technologies to reduce the accidents that happen to the workers or any human resource errors.

Countries such as France and Spain are expected to grow at a healthy CAGR in the coming years.

KEY MARKET PLAYERS:

Sun Pharmaceutical Industries Ltd, Merck & Co. Inc., Panacea Biotec Limited, GlaxoSmithKline Plc, Medigen Vaccine Biologics Corporation, Biological E Ltd, Sanofi Pasteur Limited, GeneOne Life Science Inc, Serum Institute of India Pvt. Ltd and Takeda Pharmaceutical Company Limited are some of the notable companies in the European dengue vaccines market.